Unique immunological profile in patients with COVID-19

被引:0
作者
Stefania Varchetta
Dalila Mele
Barbara Oliviero
Stefania Mantovani
Serena Ludovisi
Antonella Cerino
Raffaele Bruno
Alberto Castelli
Mario Mosconi
Marco Vecchia
Silvia Roda
Michele Sachs
Catherine Klersy
Mario U. Mondelli
机构
[1] Fondazione IRCCS Policlinico San Matteo,Division of Infectious Diseases II and Immunology
[2] University of Pavia,Department of Internal Medicine and Therapeutics
[3] Fondazione IRCCS Policlinico San Matteo,Division of Infectious Diseases I
[4] University of Pavia,Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences
[5] Fondazione IRCCS Policlinico San Matteo,Division of Orthopaedics and Traumatology
[6] University of Pavia,Department of Clinical
[7] IRCCS Fondazione Policlinico San Matteo,Surgical, Diagnostic and Pediatric Sciences
来源
Cellular & Molecular Immunology | 2021年 / 18卷
关键词
COVID-19; NK cells; TIM-3; IL6; Monocytes;
D O I
暂无
中图分类号
学科分类号
摘要
The relationship between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and host immunity is poorly understood. We performed an extensive analysis of immune responses in 32 patients with severe COVID-19, some of whom succumbed. A control population of healthy subjects was included. Patients with COVID-19 had an altered distribution of peripheral blood lymphocytes, with an increased proportion of mature natural killer (NK) cells and low T-cell numbers. NK cells and CD8+ T cells overexpressed T-cell immunoglobulin and mucin domain-3 (TIM-3) and CD69. NK cell exhaustion was attested by increased frequencies of programmed cell death protein 1 (PD-1) positive cells and reduced frequencies of natural killer group 2 member D (NKG2D)-, DNAX accessory molecule-1 (DNAM-1)- and sialic acid-binding Ig-like lectin 7 (Siglec-7)-expressing NK cells, associated with a reduced ability to secrete interferon (IFN)γ. Patients with poor outcome showed a contraction of immature CD56bright and an expansion of mature CD57+ FcεRIγneg adaptive NK cells compared to survivors. Increased serum levels of IL-6 were also more frequently identified in deceased patients compared to survivors. Of note, monocytes secreted abundant quantities of IL-6, IL-8, and IL-1β which persisted at lower levels several weeks after recovery with concomitant normalization of CD69, PD-1 and TIM-3 expression and restoration of CD8+ T cell numbers. A hyperactivated/exhausted immune response dominate in severe SARS-CoV-2 infection, probably driven by an uncontrolled secretion of inflammatory cytokines by monocytes. These findings unveil a unique immunological profile in COVID-19 patients that will help to design effective stage-specific treatments for this potentially deadly disease.
引用
收藏
页码:604 / 612
页数:8
相关论文
共 32 条
[1]  
Huang C(2020)Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China Lancet 395 497-506
[2]  
Hoffmann M(2020)SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Cell 181 271-280
[3]  
Ramos Casals M(2014)Adult haemophagocytic syndrome Lancet 383 1503-1516
[4]  
Ruan Q(2020)Clinical Predictors of Mortality Due to COVID-19 Based on an Analysis of Data of 150 Patients From Wuhan, China Intensive Care Med. 46 846-848
[5]  
Blanco-Melo D(2020)Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 Cell 181 1036-1045
[6]  
McKecnie JL(2020)The innate immune system: fighting on the front lines or fanning the flames of COVID-19? Cell Host Microbe. 27 863-886
[7]  
Blish CA(2020)Functional exhaustion of antiviral lymphocytes in COVID-19 patients Cell Mol. Immunol. 17 533-535
[8]  
Zheng M(2020)Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure Cell Host Microbe 27 992-1000.e3
[9]  
Giamarellos-Bourboulis EJ(2020)Marked T cell activation, senescence, exhaustion and skewing toward TH17 in patients with COVID-19 pneumonia Nat. Commun. 11 102473-23
[10]  
De Biasi S(2020)Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience J. Autoimmun. 112 14-1351